Life Sciences

  • June 15, 2026

    Squires Rejects 7 AIA Cases, Explains Earlier Tesla Decision

    U.S. Patent and Trademark Office Director John Squires has granted five patent challenges and rejected seven others, and he also issued a decision Monday explaining why he allowed a group of Tesla petitions to go ahead to the merits stage of review.

  • June 15, 2026

    Univ. Of Washington Beats Medical Prof's Bias Suit At Trial

    Jurors have cleared the University of Washington's medical school of liability in an anesthesiology professor's lawsuit alleging that she was unfairly ousted from a director role after complaining of discrimination and harassment, finding that the professor failed to sufficiently prove any of her three claims against the school.

  • June 15, 2026

    FTC Pulls OptumRx Insulin Price Case To Review Final Deal

    The Federal Trade Commission's third and final settlement resolving an in-house case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes is in sight after the agency on Friday pulled from adjudication its allegations against UnitedHealth Group Inc.'s OptumRx to review a deal struck with staffers.

  • June 15, 2026

    $239M LabCorp Deal Illegally Shared Genetic Info, Suit Says

    Genetic testing company Invitae Corp. has been hit with proposed class privacy claims by an Illinois parent who says the company unlawfully disclosed its patients' genetic information to LabCorp after the laboratory testing giant bought Invitae out of bankruptcy.

  • June 15, 2026

    CareFirst Says Intent Standard Was Misread In Stelara Case

    CareFirst is arguing that a Virginia federal judge created a new standard for monopolization claims when he dismissed claims from the company's antitrust suit challenging Johnson & Johnson's protection of its immunosuppressive drug Stelara, arguing he misread a Fourth Circuit decision in ruling that monopolization requires a showing of specific intent.

  • June 15, 2026

    Mead Johnson Wins New Trial Over $60M NEC Formula Verdict

    An Illinois appellate panel has thrown out a $60 million jury verdict awarded to a mother claiming Mead Johnson's infant formula caused her premature baby to develop a fatal gut disease, saying the trial court erred in finding the company owed a duty to warn the mother and not just the infant's doctors, and allowing prejudicial evidence about Mead Johnson's profits.

  • June 15, 2026

    Wyo. Judge Nixes 3 Abortion Care Limits As Unconstitutional

    A Wyoming judge has struck down three state laws restricting abortion care, finding that the state failed to demonstrate it had a compelling interest in effectuating a 48-hour waiting period for abortions and requiring certain abortion facilities to be licensed as ambulatory surgical centers, among other restrictions.

  • June 15, 2026

    Nano-X Investors Sue Over Korea Plant Restructuring Hit

    Medical imaging company Nano-X Imaging Ltd. faces a proposed investor class action alleging it failed to tell investors that it had expanded its manufacturing operations beyond what customer demand justified, ultimately leading to a $17.5 million write-down.

  • June 15, 2026

    Hagens Berman Must Cover Fees After Misconduct Findings

    Hagens Berman Sobol Shapiro LLP must cover the fees and costs of a special master who alleged the firm committed misconduct in product liability litigation over the morning sickness drug thalidomide, a Pennsylvania federal judge has said.

  • June 15, 2026

    Mylan Investor Claims Atty Fees Too Much For 'Lost' Case

    An attorney and stockholder in the former Mylan NV objected to the attorneys' fees in a proposed $60 million class action settlement, telling a Pennsylvania federal judge Monday that the plaintiffs' lawyers effectively "lost" a suit that began with allegations of $5.1 billion in lost share value.

  • June 15, 2026

    Judge Gives First OK To $69M ChemoCentryx Deal

    A California federal judge has given the first green light to a $69 million settlement reached between investors and ChemoCentryx, resolving claims that the California-based pharmaceutical company overstated the efficacy of its newly developed treatment for autoimmune disease ANCA vasculitis.

  • June 12, 2026

    Jury Tells Amgen To Pay $20.2M In Antibody Patent Trial

    A Delaware federal jury decided Friday that Amgen Inc. and its Teneobio Inc. unit willfully infringed a mouse antibody patent asserted by Harbour Antibodies BV and others, and should pay $20.2 million in damages — the full amount Harbour was seeking.

  • June 12, 2026

    J&J Trial Over Doctor's Cancer Death Ends In Settlement

    A long-running dispute over whether Johnson & Johnson's baby powder caused the cancer that killed a Miami anesthesiologist concluded with a settlement just before closing arguments in a second trial after the first ended in a hung jury. 

  • June 12, 2026

    Disability Rights Orgs. Seek To Halt NY, Ill. 'Aid-In-Dying' Laws

    Disability rights organizations hit the governors of New York and Illinois with a pair of federal lawsuits seeking to stop new laws in each state from taking effect that would allow patients with terminal illnesses to seek a doctor's assistance in ending their lives.

  • June 12, 2026

    Zoetis Brass Face Derivative Suit Over Pet Meds Statements

    Directors and officers of animal health company Zoetis Inc. have been hit with shareholder derivative claims that they breached their fiduciary duties by concealing that safety warnings about one of its products and increasing competition were hurting the company's bottom line.

  • June 12, 2026

    Insider Trading Defense May Draw On 'Varsity Blues' Playbook

    After enlisting a crew of experienced attorneys, defendants charged in an insider trading case allegedly involving deal information stolen from huge law firms are preparing to use a strategy that could take some cues from the "Varsity Blues" case in the same Boston courthouse.

  • June 12, 2026

    Ex-Honeywell China GC Can't Bring US Bias Suit, Judge Says

    Honeywell International Inc. defeated a lawsuit alleging it unlawfully fired the vice president and general counsel at a Chinese subsidiary because she turned 55, with a North Carolina federal judge saying her employment contract requires the dispute to be handled in China.

  • June 12, 2026

    Taxation With Representation: Gibson Dunn, Davis Polk, S&C

    In this week's Taxation With Representation, SpaceX prices a $75 billion initial public offering at its designated price range, Apollo Global Management leads a capital commitment for a Broadcom initiative to build artificial intelligence infrastructure for companies including Anthropic, and pharma giant GSK acquires cancer therapy specialist Nuvalent.

  • June 11, 2026

    AbbVie Loses Colorado 340B Drug Pricing Law Challenge

    A Colorado federal judge on Wednesday dismissed all of AbbVie Inc.'s claims against the state over its federal 340B drug pricing law, finding that the Colorado law isn't federally preempted and courts across the country have settled the issue.

  • June 11, 2026

    Ex-Pharma Exec Fights SEC 'Shadow Trading' Win At 9th Circ.

    An ex-Medivation Inc. executive urged the Ninth Circuit on Thursday to scrap a jury verdict finding him liable in the U.S. Securities and Exchange Commission's first-ever "shadow trading" case, arguing the company's own policies permitted the trades and affirming the verdict will allow companies to adopt vague trading policies.

  • June 11, 2026

    11th Circ. Seeks Fla., Ga. Justices' Input On Opioid Coverage

    The Eleventh Circuit on Thursday asked justices in Georgia and Florida to weigh in on whether commercial general liability insurers must defend and indemnify Publix Super Markets Inc. and a Georgia-based generic-drug wholesaler against suits claiming they improperly distributed opioids.

  • June 11, 2026

    Stop & Shop Parent Pays $40M On Inflated Drug Price Claims

    Stop & Shop's parent company will pay $40 million to resolve allegations it violated the False Claims Act by failing to report discounted prescription drug prices as "usual and customary" in claims submitted to federal Medicare, Medicaid and TRICARE programs, which resulted in overcharges, the U.S. Department of Justice announced Wednesday.

  • June 11, 2026

    Chinese Biopharma Sues Over National Security Threat Label

    Chinese pharmaceutical company WuXi AppTec sued the U.S. Department of Defense on Thursday, asking a D.C. federal court to set aside the agency's designation of the company as a Chinese military company, which it said was done "without a lawful or factual basis."

  • June 11, 2026

    23andMe To Pay $46.7M To Resolve Data Breach Claims

    The plan administration trust created under the Chapter 11 plan of DNA-testing company 23andMe has struck a deal to pay $46.7 million to data breach claimants, saying the move brings 23andMe one step closer to resolving the fallout of a massive data breach in 2023.

  • June 11, 2026

    Cancer Diagnostics Firm Ignite Inks $150M SPAC Merger

    Precision oncology startup Ignite Proteomics LLC will merge with special purpose acquisition company Copley Acquisition Corp. in a deal valuing Ignite at a pro forma enterprise value of $150 million, the companies announced Thursday.

Expert Analysis

  • DTSA Data Shows Hidden Value Of Ex Parte Seizure Filings

    Author Photo

    Ten years of Defend Trade Secrets Act data indicate that although there is a low success rate for civil seizure applications, intellectual property litigators should continue filing them anyway in order to better their odds of obtaining other provisional relief, say attorneys at Reed Smith.

  • Becoming The Biz-Savvy GC That Portfolio Companies Need

    Author Photo

    Candidates for general counsel roles at private equity-backed portfolio companies should prioritize proving their sector-specific experience, commercial judgment and ease with uncertainty — and attorneys hoping to be candidates in five to 10 years should start working on those skills now, says Dimitri Mastrocola at Major Lindsey.

  • AI Regulatory Gaps May Fuel FCA Enforcement Action

    Author Photo

    The intersection of artificial intelligence and False Claims Act enforcement presents legal risk for government contractors across several industries, particularly in the absence of a federal regulatory framework explicitly governing its development and use, say attorneys at O’Melveny.

  • Series

    Judges On AI: How Courts Can Survive The Tech Revolution

    Author Photo

    Colorado Supreme Court Justice Maria Berkenkotter and Colorado Court of Appeals Judge Lino Lipinsky de Orlov discuss how artificial intelligence has already fundamentally altered the legal system and offer tips for courts navigating deepfakes, hallucinations and a gap in access to AI tools.

  • 'Skinny Label' Arguments Spotlight Induced Infringement Risk

    Author Photo

    Recent oral arguments before the U.S. Supreme Court in Hikma Pharmaceuticals v. Amarin Pharma highlight the uncertain boundary between lawful generic competition through so-called skinny labels and induced patent infringement, with potential implications for patent holders’ communication, enforcement and causation strategies across industries, says Anton Hopen at Trenam.

  • Startup Founder Disputes Increasingly Turn On Governance

    Author Photo

    Recent Delaware developments suggest that as courts place increasing emphasis on board process, independence and oversight in founder-led startups, the growing intersection of governance, technology risk and investor oversight is accelerating both the emergence and escalation of founder disputes, says mediator Frank Burke.

  • 3 AI Adoption Mistakes GCs Should Avoid

    Author Photo

    The pressure in-house legal teams face to quickly adopt artificial intelligence tools, combined with budget constraints and the need to evaluate a crowded market of options, sets the stage for implementation mistakes that are often difficult to undo, says former 23andMe general counsel Guy Chayoun.

  • Series

    Playing Basketball Makes Me A Better Lawyer

    Author Photo

    My grandfather used to say "I wear your jersey" as shorthand for wholly committing to support someone with loyalty and integrity — ideals that have shaped my life on the basketball court and in legal practice, says Tracy Schimelfenig at Schimelfenig Legal.

  • EPA Listing Signals New Scrutiny Of Drugs In Drinking Water

    Author Photo

    The recent publication of the U.S. Environmental Protection Agency's latest draft drinking water contaminant list highlights pharmaceuticals as a category of concern, marking the start of a process that could shape future research priorities, monitoring requirements, and federal and state actions, say attorneys at Morgan Lewis.

  • How Del. Courts Will Likely Evaluate AI Oversight Claims

    Author Photo

    While no Delaware court has thus far adjudicated a claim based on alleged board failures to oversee artificial intelligence risk, recent Court of Chancery decisions suggest that familiar Caremark principles will be applied in predictable but consequential ways, particularly when AI touches mission‑critical operations, say attorneys at WilmerHale.

  • Opinion

    5th Circ.'s Abortion Pill Order Is Shaky On Multiple Grounds

    Author Photo

    The Fifth Circuit's recent order in Louisiana v. U.S. Food and Drug Administration, reinstating an in-person dispensing requirement for the abortion medication mifepristone, seems to turn federalism upside-down, and is also questionable for several other reasons, says Gregory Curtner at Curtner Law.

  • Series

    The Biz Court Digest: Georgia Court Has Business On Its Mind

    Author Photo

    Thanks to recent legislation, the Georgia State-wide Business Court will soon offer business litigants greater access to the court than ever before, further enhancing the court's emphasis on efficiency, predictability and accessibility for sophisticated commercial disputes, says former GSBC judge Walt Davis at Jones Day.

  • Opinion

    USPTO Must Address The Right Question In Sanofi Case

    Author Photo

    The U.S. Patent and Trademark Office Appeals Review Panel's questions in Ex parte Baurin indicate recognition of broader doctrinal issues, but rather than approaching from separate angles, the panel should concentrate on a single fundamental question about obviousness-type double patenting, says Jeremy Lowe at Spencer Fane.

  • 4 Emerging Approaches To AI Protective Order Language

    Author Photo

    Over the last year, at least five federal district courts have issued or analyzed specific protective order provisions restricting the use of generative artificial intelligence platforms with protected materials, establishing that proactive AI-specific provisions are now standard practice and demonstrating that no single model works for every case, says Joel Bush at Kilpatrick.

  • What Justices Are Focusing On In 'Skinny Label' Patent Case

    Author Photo

    Though Hikma v. Amarin appears to be a patent dispute that could reshape inducement doctrine in the pharmaceutical context, oral argument suggests the U.S. Supreme Court may treat this as primarily a pleading-stage dispute, with important unresolved questions lurking beneath the surface, says Shashank Upadhye at Upadhye Tang.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.